Association between expression of cancer stem cell markers and poor differentiation of hepatocellular carcinoma: A meta-analysis (PRISMA)

Medicine (United States)

Volumn 94, Issue 31, 2015, Pages

  Liu, Rui ^a   Shen, Yuan ^b   Nan, Kejun ^a   Mi, Baibing ^b   Wu, Tao ^a   Guo, Jinyue ^a   Li, Miaojing ^a   Lv, Yi ^b   Guo, Hui ^a   Qi, Peng ^c  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CD133 ANTIGEN; CELL MARKER; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; THY 1 ANTIGEN; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TUMOR ANTIGEN;

ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER PATIENT; CANCER STEM CELL; CANCER TISSUE; CELL DIFFERENTIATION; CHEMOEMBOLIZATION; CONFIDENCE INTERVAL; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; EFFECT SIZE; EMBASE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER RESECTION; MEDLINE; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PATIENT CODING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; LIVER TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANTIGENS, CD; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; HUMANS; LIVER NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84942430819     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001306     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA. 2011; 61: 69-90.
2. Liu M, Jiang L, Guan XY. The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. Protein Cell. 2014; 5: 673-691.
3. Altekruse SF, Henley SJ, Cucinelli JE, et al. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014; 109: 542-553.
4. Wittekind C. Pitfalls in the classification of liver tumors. Der Pathol. 2006; 27: 289-293.
5. Oostra DR, Macrae ER. Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer. Breast Cancer. 2014; 6: 103-113.
6. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13: 239-246.
7. Majumdar A, Curley SA, Wu X, et al. Hepatic stem cells and transforming growth factor beta in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2012; 9: 530-538.
8. Mishra L, Banker T, Murray J, et al. Liver stem cells and hepatocellular carcinoma. Hepatology. 2009; 49: 318-329.
9. Feng D, Wang N, Hu J, et al. Surface markers of hepatocellular cancer stem cells and their clinical potential. Neoplasma. 2014; 61: 505-513.
10. Chan AW, Tong JH, Chan SL, et al. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. Histopathology. 2014; 64: 935-950.
11. Chen ZL, Jiang P, Zhang X, et al. CD44, CD133 and TF correlate with formation of portal vein tumor thrombus and poor prognosis in patients with hepatocellular carcinoma. J Third Mil Med Univ. 2014; 36: 1068-1073.
12. Cheng BQ, Jiang Y, Li DL, et al. Up-regulation of Thy-1 promotes invasion and metastasis of hepatocarcinomas. Asian Pac J Cancer Prev. 2012; 13: 1349-1353.
13. Gao AS, Li JG. The expression and significance of CD44v6, MMP and VEGF in hepatocellular carcinoma. Shandong Med J. 2008; 48: 30-31.
14. Govaere O, Komuta M, Berkers J, et al. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut. 2014; 63: 674-685.
15. Guan XQ, Xu M, Li YY, et al. The observation of CD44 OR differentiation and vascular invasion in hepatocellular carcinoma. J Chongqing Med Univ. 2002; 27: 3.
16. Guo LL, Guo Y, Cao CA. The expression and significance of CD54, CD44 and E-cadherin in hepatocellular carcinoma. Chin J Gen Surg. 2000; 9: 3.
17. Guo Z, Li LQ, Jiang JH, et al. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma. World J Gastroenterol. 2014; 20: 2098-2106.
18. Lingala S, Cui YY, Chen X, et al. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp Mol Pathol. 2010; 89: 27-35.
19. Liu W, Wang ZY, Bai XY, et al. Expression and clinical significance of FN and CD44v6 in hepatocellular carcinoma. Chin J Clin Oncol. 2009; 36: 3.
20. Liu LL, Liu W, Li YJ. Expressions of CD133 and CD90 in hepatocellular carcinoma tissue and their clinical significance. Acad Med Qingdao Univ. 2013; 49: 4.
21. Lu JW, Chang JG, Yeh KT, et al. Overexpression of Thy1/CD90 in human hepatocellular carcinoma is associated with HBV infection and poor prognosis. Acta Histochem. 2011; 113: 833-838.
22. Pan QX, Su ZJ, Wang CR, et al. Expressions of tumor stem cell markers EpCAM and CD133 in human primary hepatocellular carcinoma and their value in prognostic prediction. Tumor. 2012; 32: 5.
23. Salnikov AV, Kusumawidjaja G, Rausch V, et al. Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett. 2009; 275: 185-193.
24. Sasaki A, Kamiyama T, Yokoo H, et al. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol Rep. 2010; 24: 537-546.
25. Song W, Li H, Tao K, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract. 2008; 62: 1212-1218.
26. Tsuchiya A, Kamimura H, Takamura M, et al. Clinicopathological analysis of CD133 and NCAM human hepatic stem/progenitor cells in damaged livers and hepatocellular carcinomas. Hepatol Res. 2009; 39: 1080-1090.
27. Wu LM, Chen XX, Cheng CT, et al. Expression of CD133 and VEGF in hepatocellular carcinoma and its prognostic value. Chin J Liver Dis. 2013; 5: 5.
28. Xu M, Qian G, Xie F, et al. Expression of epithelial cell adhesion molecule associated with elevated ductular reactions in hepatocellar carcinoma. Clin Res Hepatol Gastroenterol. 2014; 38: 699-705.
29. Yamashita T, Forgues M, Wang W, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008; 68: 1451-1461.
30. Yeh CT, Kuo CJ, Lai MW, et al. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer. 2009; 9: 324.
31. Yilmaz G, Akyol G, Cakir A, et al. Investigation of diagnostic utility and expression profiles of stem cell markers (CD133 and CD90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosis. Pathol Res Pract. 2014; 210: 419-425.
32. Yu XH, Xu LB, Liu C, et al. Clinicopathological characteristics of 20 cases of hepatocellular carcinoma with bile duct tumor thrombi. Dig Dis Sci. 2011; 56: 252-259.
33. Zeng XC, Zhang T, Fu BS, et al. Expression of CD133 as a tumor stem cell marker in hepatocellular carcinoma and its significance in the prognosis of liver transplantation patients. Chin J Hepat Surg. 2012; 1: 5.
34. Zhang QG, Li YP. Detection of CD44v6 and its clinical significance in hepatocellular carcinoma. Chin J Clin Oncol Rehabil. 2002; 3: 2.
35. Zheng WH, Yang WB, Fu CB, et al. Expression of KAI1 protein and its relationship with CD44v6 in HCC and prognosis study. China J Mod Med. 2007; 20: 4.
36. Zheng SW, Zhao HW, Wang W, et al. The expression and clinical significance of CD90, IGF1R, and hTERT protein in hepatocellular carcinoma. Chin J Bases Clin Gen Surg. 2012; 19: 6.
37. Zeuner A, Todaro M, Stassi G, et al. Colorectal cancer stem cells: from the crypt to the clinic. Cell Stem Cell. 2014; 15: 692-705.
38. Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov. 2014; 13: 497-512.
39. Yin C, Lin Y, Zhang X, et al. Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. Hepatology. 2008; 48: 1528-1539.
40. Lin L, Amin R, Gallicano GI, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene. 2009; 28: 961-972.
41. Yamashita T, Honda M, Nio K, et al. Oncostatin M renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-fluorouracil by inducing hepatocytic differentiation. Cancer Res. 2010; 70: 4687-4697.
42. Zhang KZ, Zhang QB, Zhang QB, et al. Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model. J Hematol Oncol. 2014; 7: 28.
43. Ma YC, Yang JY, Yan LN. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis. Eur J Gastroenterol Hepatol. 2013; 25: 1007-1016.
44. Zhong C, Wu JD, Fang MM, et al. Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis. Tumour Biol. 2015 [Epub ahead of print].
45. Takebe N, Miele L, Harris PJ, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015 [Epub ahead of print].